|
Jan 2
|
Roche to buy LumiraDx’s point-of-care technology for $295M
|
|
Jan 2
|
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
|
|
Dec 29
|
Roche to buy part of LumiraDx diagnostics platform for $295 million
|
|
Dec 29
|
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
|
|
Dec 21
|
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
|
|
Dec 20
|
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
|
|
Dec 20
|
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
|
|
Dec 19
|
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
|
|
Dec 19
|
Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
|
|
Dec 11
|
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
|
|
Dec 9
|
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
|
|
Dec 9
|
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
|
|
Dec 8
|
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
|
|
Dec 8
|
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
|
|
Dec 8
|
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
Dec 8
|
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
|
Dec 8
|
Why Viking Therapeutics Was Crushing It This Week
|
|
Dec 7
|
The Zacks Analyst Blog Highlights Alphabet, NVIDIA, Roche, Intuit and AT&T
|
|
Dec 6
|
Top Research Reports for Alphabet, NVIDIA & Roche
|
|
Dec 5
|
UPDATE 2-Merck KGaA suffers major blow as MS drug fails in late-stage trials
|